An estimated 9.0 million people aged 12 or older in the United States misused central nervous system stimulants in the past year, including 4.3 million who used cocaine and 1.6 million who used methamphetamine (SAMHSA NSDUH 2024). Stimulant-involved overdose deaths have risen sharply, with the rate involving cocaine nearly doubling from 4.5 to 8.6 per 100,000 between 2018 and 2023, and the rate involving methamphetamine rising from 3.9 to 10.4 over the same period (CDC). The Stepwell Center treats stimulant use disorder as the clinical condition it is, with a written plan and a defined modality mix, alongside the other substance use conditions we cover.
Recognition usually arrives gradually. Use that began as recreational or performance-driven has crept upward, doses needed to reach the same effect have grown, sleep and appetite have begun to organize around the cycle, and the crashes between use have become harder to absorb. Cardiac, dental, and mental health symptoms often appear before the pattern is named. The clinical definition follows that picture. Stimulant use disorder meets the same diagnostic frame as any substance use disorder, diagnosed when at least two of eleven criteria appear in a twelve-month period, with severity rated mild, moderate, or severe (NIDA). Outpatient care is appropriate across that range when the assessment indicates the level of structure that fits.
Your plan begins with a 2 to 3 day comprehensive assessment that integrates clinical interview, qEEG brain mapping, pharmacogenetic testing when medication for a co-occurring condition is on the table, and standardized psychological testing. The output is a written care plan that names the modalities, the medication considerations for any co-occurring depression, anxiety, or ADHD, and the level of care that fits your clinical profile. The plan is delivered across PHP, IOP, Evening IOP, and Outpatient at our Lakeway, Texas facility in the Lake Travis corridor, by the same clinical team across each step.